Tune in to compliance
26 April 2010
Sensohaler uses advanced acoustic analysis to understand how an inhaler is functioning and how it is being used by the patient. It provides valuable feedback to the user, doctor or provider and consequently promotes correct use. It will increase compliance through positive user feedback, help doctors to understand the efficacy of the medication and help drug providers learn how their products perform early on in clinical trials.
The technology comprises a microphone sensor and a chip for signal analysis that would sit in or on the inhaler. It accurately measures and monitors key performance characteristics – such as flowrate, inhaled volume and peak inspiratory flowrate – during the inspiratory manoeuvre and confirms events such as the firing of a breath actuation mechanism (BAM) and delivery of the formulation through the airway of the device.
The technique is completely non-invasive, having no effect on the airflow or the aerosolisation performance of the inhaler and (if required) could be imperceptible to the user. A feasibility study using Sensohaler demonstrated the accuracy of the technology on a range of different devices and inhaler types. It proved with two different inhaler types that the flowrate accuracy is on par with that of a thermal mass flowmeter.
Iain Simpson, who recently joined from Team Consulting to head up Sagentia’s growing Drug Delivery team, said: “Non compliance in inhaled drug delivery is a big issue - providing direct feedback to users will help reinforce correct usage and also assist clinicians in working with their patients to improve management of their disease”
The Sensohaler technology is being demonstrated on Sagentia’s stand at the leading Respiratory Drug Delivery (RDD) Conference, being held 25-29 April in Orlando. The conference includes in-depth discussions of the developing issues surrounding aerosol drug delivery, including new therapeutic opportunities and drug design technologies, progress in drug development alongside novel in vitro and in vivo testing methods and regulatory science.
Visit Sagentia’s stand and speak to its Drug Delivery team to find out about the latest innovation thinking in the medical field. Visitors to the stand will also have the chance to take part in Sagentia’s ‘Test your lung power’ challenge, using another technology demonstrator that is being used to characterise lungs against different constraints.
Read more about Sensohaler.
For more information please contact:
Charlotte Gynane
MarComms & PR Coordinator
charlotte.gynane@sagentia.com
Tel: +44 (0) 1223 875 585
Notes for Editors:
About Sagentia
Sagentia creates, develops and delivers business opportunities, products and services for its clients.
Established in 1986, Sagentia operates in the medical, industrial products and consumer products sectors worldwide. It develops new technologies, products and services that change the basis of competition. The company also assists business leaders to create strategies for technology, innovation and growth.
Sagentia has expanded its medical activity significantly over recent years and has a strong track record in the sector. Its drug delivery areas of expertise include OINDP (Orally Inhaled and Nasal Drug Products) and injectables, dry powder inhaler (DPI) programmes, MDIs, nebulisers, nasal delivery systems, breath actuation mechanisms and dose counters.
Sagentia’s resources are situated in state-of-the-art facilities in Europe, the USA, and China. The Group is listed on AIM (ti: SAG.L).
www.sagentia.com
info@sagentia.com